← Human Trials & Peer-Reviewed Studies
Lack of value of midregional pro-adrenomedullin and C-terminal pro-endothelin-1 for prediction of severe bacterial infections in infants with fever without a source
Plain-language guide to PMID 23793138 (2013): multicenter clinical trial study of Adrenomedullin and Endothelin-1 in 1,035 infants.
Key Facts
- PMID
- 23793138
- Journal
- European journal of pediatrics
- Year
- 2013
- Study type
- Clinical Trial
- Authors
- Benito J et al. (7 authors)
- DOI
- 10.1007/s00431-013-2062-z
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Adrenomedullin and Endothelin-1, published as a clinical trial.
The study was performed to assess the usefulness of two new biomarkers, midregional pro-adrenomedullin (MR-pro-ADM) and C-pro-endothelin-1 (CT-pro-ET-1), in predicting bacterial infection (BI) and especially invasive bacterial infection (IBI) in well-appearing infants with fever without source (FWS).
For this purpose, a multicenter prospective study was conducted between February 2008 and March 2009 including well-appearing infants less than 36 months of age with FWS.
Why It Was Studied
MR-pro-ADM and CT-pro-ET-1 levels were less reliable for diagnosis than the other biomarkers.
PCT was the only independent risk factor for having an IBI (OR 17.53 if PCT ≥ 0.5 ng/mL).
Who Took Part
The abstract describes 1,035 infants taking part.
The age groups tagged for this paper are infants, both men and women.
How the Study Was Run
In design terms this was a multicenter study.
Running at several centres spread the Adrenomedullin study over different clinics and patient groups.
MR-pro-ADM, CT-pro-ET-1, procalcitonin (PCT), CRP, and WBC were measured and compared.
What Was Measured
MR-pro-ADM and CT-pro-ET-1 levels were less reliable for diagnosis than the other biomarkers.
Topics PubMed links to this paper include Adrenomedullin, Bacterial Infections, Biomarkers, C-Reactive Protein, Calcitonin, Calcitonin Gene-Related Peptide and Endothelin-1.
What This Means in Plain Language
The paper is a multicenter study of Adrenomedullin and Endothelin-1 in 1,035 infants.
With several hundred people or more, it is a fairly large study for this kind of research.
Results are reported in around 1 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2013 (European journal of pediatrics), a journal based in Germany.
More context: the Adrenomedullin compound page and the Endothelin-1 compound page, all human trials.
Our Notes on the Compounds
Adrenomedullin: A 52-amino-acid peptide that widens blood vessels; studied as an infusion in heart, lung and gut conditions.
Endothelin-1: A 21-amino-acid peptide and one of the strongest blood-vessel constrictors in the body; given in research studies of vascular function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.